supplementary material

[키워드] 1:1 absence acutely ill hospitalized medical patients Admission age allergy allocation concealment allocation sequence Alpha America and protocol Anticoagulant anticoagulation antiplatelet antithrombotic therapy apixaban arterial bleeding bleeding risk Blinding block sizes blood cell Brazil can not Canada Care Chain Reaction changed choice clinical trial clinically clinician Coagulation Coagulopathy Committee complex Composite computer-generated contraindication control group Controlled COVID COVID-19 Critical Critical illness cryoprecipitate D-dimer D-dimer value Dabigatran dalteparin Date death defined dependent on detect determine diagnosis of SARS-CoV-2 diagnostic Diagnostic imaging discretion disorder dissemination dose dual edoxaban electrocardiogram element elevated emergency room enoxaparin Enrollment evaluated exclusion criteria expected experimental group fibrinogen fondaparinux frozen plasma Health Organization hemoglobin heparin heparin-induced thrombocytopenia High dose high risk hospital Hospital admission hospitalised Hospitalized hospitalized patient hospitalized patients ICU ICU admission include inclusion criteria indicated individual inflammatory biomarkers Informed consent INR intensive care intensive care unit Interactive Web Response System intermediate dose Invasive mechanical ventilation involved Ireland isothermal amplification judgement limit LMWH Local low molecular weight low molecular weight heparin Major major bleeding mechanical ventilation Non-invasive non-invasive positive pressure ventilation nucleic acid number objective occur Open-label open-label trial outcome oxygen oxygen saturation participant Patient patients Phase 3 plasma Platelet Platelet count Platelets polymerase chain polymerase chain reaction positive pressure positive pressure ventilation power Pregnancy pressure ventilation protocol random random allocation randomised randomised controlled trial randomization Randomized controlled trial Rapid recruited red blood cell renal replacement therapy replacement therapy response responsible reverse transcriptase Reverse transcriptase polymerase chain reaction risk risk difference rivaroxaban room air Sample size Saudi Arabia secondary Secondary outcomes Standard standard care status stratified study population Study protocol supplementary material symptomatic the patient the United State therapeutic anticoagulation therapeutic dose therapy thrombocytopenia Thromboembolism Thromboprophylaxis tinzaparin transcriptase transfusion treated Trial Trial registration two-sided ULN unfractionated heparin United Arab Emirates United States Venous Thromboembolism Ventilator-free days Version Warfarin website World Health Organization
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter